Published on September 25, 2009 at 4:01 AM
NicOx S.A. (NYSE Euronext Paris: COX) today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
Michele Garufi, Chairman and CEO of NicOx, declared: "The submission of a New Drug Application is a tremendous achievement for any company and represents a particularly important milestone for NicOx. This accomplishment represents another major step in NicOx' planned transformation into a self-sustainable pharmaceutical company, able to make significant contributions to the successful commercialization of naproxcinod. To achieve this key corporate goal, we continue to focus on building NicOx' future commercial operations in the US."
SOURCE: NICOX
29e6c915-b397-4f15-bb2b-4c37921aa86c|1|5.0
Posted in: Pharmaceutical News
Tags: Anti-Inflammatory, Arthritis, Atherosclerosis, Blood Pressure, Cartilage, New Drug Application, Nitric Oxide, Obesity, Osteoarthritis, Pharmacology, Valdecoxib